These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 22648179)

  • 1. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.
    Beeram M; Krop IE; Burris HA; Girish SR; Yu W; Lu MW; Holden SN; Modi S
    Cancer; 2012 Dec; 118(23):5733-40. PubMed ID: 22648179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
    Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
    J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
    Krop IE; Beeram M; Modi S; Jones SF; Holden SN; Yu W; Girish S; Tibbitts J; Yi JH; Sliwkowski MX; Jacobson F; Lutzker SG; Burris HA
    J Clin Oncol; 2010 Jun; 28(16):2698-704. PubMed ID: 20421541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
    Gupta M; Lorusso PM; Wang B; Yi JH; Burris HA; Beeram M; Modi S; Chu YW; Agresta S; Klencke B; Joshi A; Girish S
    J Clin Pharmacol; 2012 May; 52(5):691-703. PubMed ID: 21953571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Hurvitz SA; Dirix L; Kocsis J; Bianchi GV; Lu J; Vinholes J; Guardino E; Song C; Tong B; Ng V; Chu YW; Perez EA
    J Clin Oncol; 2013 Mar; 31(9):1157-63. PubMed ID: 23382472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer.
    Bender BC; Schaedeli-Stark F; Koch R; Joshi A; Chu YW; Rugo H; Krop IE; Girish S; Friberg LE; Gupta M
    Cancer Chemother Pharmacol; 2012 Oct; 70(4):591-601. PubMed ID: 22886072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis.
    Diéras V; Harbeck N; Budd GT; Greenson JK; Guardino AE; Samant M; Chernyukhin N; Smitt MC; Krop IE
    J Clin Oncol; 2014 Sep; 32(25):2750-7. PubMed ID: 25024070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review.
    Mathew J; Perez EA
    Curr Opin Oncol; 2011 Nov; 23(6):594-600. PubMed ID: 21986845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer.
    Yamamoto H; Ando M; Aogi K; Iwata H; Tamura K; Yonemori K; Shimizu C; Hara F; Takabatake D; Hattori M; Asakawa T; Fujiwara Y
    Jpn J Clin Oncol; 2015 Jan; 45(1):12-8. PubMed ID: 25332421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
    Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
    Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
    Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA
    Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer.
    Krop IE; Modi S; LoRusso PM; Pegram M; Guardino E; Althaus B; Lu D; Strasak A; Elias A
    Breast Cancer Res; 2016 Mar; 18(1):34. PubMed ID: 26979312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.
    Boyraz B; Sendur MA; Aksoy S; Babacan T; Roach EC; Kizilarslanoglu MC; Petekkaya I; Altundag K
    Curr Med Res Opin; 2013 Apr; 29(4):405-14. PubMed ID: 23402224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
    Krop I; Winer EP
    Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
    Welslau M; Diéras V; Sohn JH; Hurvitz SA; Lalla D; Fang L; Althaus B; Guardino E; Miles D
    Cancer; 2014 Mar; 120(5):642-51. PubMed ID: 24222194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.
    Wang J; Song P; Schrieber S; Liu Q; Xu Q; Blumenthal G; Amiri Kordestani L; Cortazar P; Ibrahim A; Justice R; Wang Y; Tang S; Booth B; Mehrotra N; Rahman A
    Clin Pharmacol Ther; 2014 May; 95(5):558-64. PubMed ID: 24488143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
    Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
    J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer.
    Li C; Wang B; Lu D; Jin JY; Gao Y; Matsunaga K; Igawa Y; Nijem I; Lu M; Strasak A; Chernyukhin N; Girish S
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):547-58. PubMed ID: 27423671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System.
    Piwko C; Prady C; Yunger S; Pollex E; Moser A
    Clin Drug Investig; 2015 Aug; 35(8):487-93. PubMed ID: 26123628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.
    Martínez MT; Pérez-Fidalgo JA; Martín-Martorell P; Cejalvo JM; Pons V; Bermejo B; Martín M; Albanell J; Lluch A
    Crit Rev Oncol Hematol; 2016 Jan; 97():96-106. PubMed ID: 26318092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.